Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
% H% b; ?" t; G0 E" ^6 L6 HNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
' t- E3 O( E' {4 R2 R6 ?+ Author Affiliations
' Y( H, b: a a$ I8 U6 P, {. s: D
& \+ @$ ]4 q* u' ?1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
) [6 T, c6 |6 u5 L y) m" p' b2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: F5 Z, W( L# C# w1 P+ G0 T3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 `: S6 R* C3 `' A3 |5 K4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. X2 {2 p; `) E& Z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
1 E6 @, I/ } ]4 W6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
% j; X8 M) r+ n% p7Kinki University School of Medicine, Osaka 589-8511, Japan . z9 S; L* J6 a/ t1 g9 n
8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 t( L! T% F+ L- w; _1 k
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
$ y5 O% x$ ?) h$ H+ gCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 2 `3 _, w' I+ I* Q6 \
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ; a; _/ {2 U0 I( H" Q. W4 H/ _
2 i3 p( t4 n4 I6 o0 @) o |